On Friday, Lincoln National Corporation (NYSE:LNC)’s shares declined -0.60% to $61.22.
Lincoln National Corporation (LNC) declared the launch of its new OptiBlendSM Fixed Indexed Annity, a flexible premium deferred fixed indexed annuity (FIA) that blends the safety of principal protection with upside market potential.
Lincoln’s new solution offers four interest crediting strategies providing clients with a combination of growth potential and capital preservation. These choices for accumulation potential comprise: a fixed account, for those who want predictable fixed account growth – without being tied to market performance; 1-year Point-to-Point Cap and Performance triggered indexed accounts tied to the performance of the S&P 500 Index and a brand new indexed account tied to a risk controlled version of the S&P 500 Index.
Lincoln’s OptiBlend features a new Volatility-Controlled Point-to-Point Indexed Account, where the interest credit is based on the performance of the S&P 500 Daily Risk Control 5% Index, giving investors exposure to the S&P 500 Index at a set risk level. A spread will be applied to the return of the S&P 500 Daily Risk Control 5% Index to determine the interest credit a client will receive. The spread acts as a hurdle rate with all index performance over the spread credited to the client’s account. Since volatility is managed within this Index, a lower spread can be offered than one based on the S&P 500 without risk control.
Lincoln’s new FIA also offers a 7 and a 10 year surrender charge period and the option to add a Guaranteed Lifetime Withdrawal Benefit (GLWB) — Lincoln Lifetime IncomeSM Edge.
Lincoln National Corporation, through its auxiliaries, engages in multiple insurance and retirement businesses in the United States. It operates through Annuities, Retirement Plan Services, Life Insurance, and Group Protection segments. The company sells a range of wealth protection, accumulation, and retirement income products and solutions. Its products comprise fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL, term life insurance, indexed universal life insurance, and employer-sponsored retirement plans and services, in addition to group life, disability, and dental products.
Intuit Inc. (NASDAQ:INTU)’s shares dropped -1.04% to $104.73.
Intuit Inc. (INTU) s coming to Atlanta to assist arm small businesses, counting entrepreneurs and self-employed workers, accountants and developers with the tools and resources they need to succeed. As part of Intuit’s commitment to small business success, QuickBooks Connect Atlanta will be held at 200 Peachtree on Thursday, June 25, 2015, and is designed to inspire, educate and connect the Atlanta business community. This one-day conference, comprising of two half-day sessions and a special event for self-employed workers, is bringing together all types of small businesses under one roof, assisting to propel their businesses forward.
QuickBooks won’t be alone – the company is coming to The Big Peach with mobile payment and shopping platform partners Square and Big commerce, converging on the city’s eclectic small business hub to bring great value to attendees. Small businesses will get hands-on advice from senior Intuit executives, in addition to Apprentice winner Bill Rancic, technology entrepreneur Jason Nazar and USA Recently small business columnist Rhonda Abrams.
Intuit Inc. provides business and financial administration solutions for small businesses, consumers, and accounting professionals in the United States, Canada, the United Kingdom, Australia, India, and Singapore. The company’s Small Business segment provides QuickBooks financial and business administration online services and desktop software; QuickBooks technical support services; financial supplies; and small business payroll products and services.
At the end of Friday’s trade, Juno Therapeutics Inc (NASDAQ:JUNO)‘s shares dipped -2.36% to $60.00.
Juno Therapeutics Inc. (JUNO) reached a contract and Plan of Merger (the “Merger Agreement”) with X-Body, Inc. (“X-Body”), X Acquisition Corporation (“Merger Sub”), Brant Binder as representative of X-Body stockholders, and certain principal stockholders of X-Body. Following the Merger Agreement, Juno attained X-Body through a merger transaction in which Merger Sub, a wholly owned partner of Juno, merged with and into X-Body, with X-Body surviving the merger as a wholly owned partner of Juno (the “Transaction”). Juno and X-Body were formerly party to a research services and license agreement, which was reached effective as of April 10, 2014.
After giving effect to a working capital adjustment, Juno paid $19.5 million in cash and issued 439,265 shares of Juno’s common stock as the initial consideration for the Transaction. Juno also paid $1.9 million in cash at the closing to satisfy liabilities and transaction expenses at X-Body that were reflected in the working capital adjustment. 72,831 of the shares issued in the Transaction, which were issued to certain ongoing service providers, are subject to vesting during the three years following the closing. Juno also agreed to pay an additional $0.5 million in cash to ongoing employees over such three year period.
In addition, additional amounts are payable in cash following the closing upon the realization of specified milestones substantially as follows, with respect to products generated using the X-Body technology: $5.0 million per target upon the achievement, during a specified period, of a certain regulatory milestone for products that utilize a certain type of binding mechanism; up to $30.0 million upon the achievement, during a specified period, of regulatory and clinical milestones for the first product using another type of binding mechanism (any product using such type of binding mechanism, a “Type X Product”); $5.0 million per product upon the achievement, during a specified period, of a certain regulatory milestone for a certain number of subsequent Type X Products; $50.0 million upon the achievement, during a specified period, of a clinical milestone related to the first product with certain specified binding properties (a “Type Y Product”); and $20.0 million upon the achievement, during a specified period, of a clinical milestone related to the first product with certain other specified binding properties. If a Type X Product or a Type Y Product is commercialized, Juno can choose either to make a commercialization milestone payment for such a product or to pay a low single-digit royalty on net sales of such a product.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates comprise JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies.
Freescale Semiconductor Ltd (NYSE:FSL), ended its Friday’s trading session with -0.52% loss, and closed at $42.07.
Freescale Semiconductor Ltd (FSL) will host the Freescale Technology Forum (FTF) Americas 2015 – one of the premier technical training events for the embedded design community – June 22-25 at the new JW Marriot in downtown Austin. Registration is now open and early bird pricing ends June 5.
Event Highlights:
- Steve Wozniak, innovator, co-founder of Apple® Computer and industry influencer. Wozniak will share his candid views on recently technical innovation, in addition to the creativity needed for tomorrow’s connected devices.
- Freescale president and CEO, Gregg Lowe is planned to reveal how Freescale is driving the Internet of Tomorrow (IoT) — a future IoT where secure solutions exist across every touch point, from the end node to the network to the cloud. Lowe will share the stage with customers and partners demonstrating innovation, moving the industry from defining IoT strategies to securing IoT implementation.
For ten years, the Freescale Technology Forum (FTF) has driven innovation and partnership by featuring one of the most comprehensive embedded ecosystems in the industry. FTF provides the training and expertise customers need to create and enable the secure, embedded solutions needed for the internet of things—recently and tomorrow. FTF features four days of in-depth training, hands-on workshops, demonstrations from Freescale and ecosystem partners and exceptional opportunities to collaborate with industry peers and visionaries. The forum has been enthusiastically received by the global developer community, drawing nearly 70,000 attendees worldwide since its inception in 2005. FTF takes place June 22-25, 2015, in Austin, Texas.
Freescale Semiconductor, Ltd. provides embedded processors worldwide. The company’s products comprise microcontrollers, ranging from 8-bit products to higher performance 16-bit and 32-bit products with on-board flash memory, which provide the digital logic or intelligence for electronic applications and controlling electronic equipment or analyzing sensor inputs; single-and multi-core microprocessors; and applications processors with embedded memory, and special purpose hardware and software for multimedia applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
